telomerase

telomerase
Name	Telomerase
Ec number	2.7.7.49
Other names	Telomerase reverse transcriptase, telomere terminal transferase
Caption	Schematic representation

telomerase

Telomerase is a ribonucleoprotein enzyme complex that extends chromosome ends by adding repetitive nucleotide sequences to telomeres in eukaryotic cells. Discovered through studies involving model organisms and human genetics, it links research communities from Murray Gell-Mann-era molecular biology to contemporary work at institutions such as Cold Spring Harbor Laboratory and Harvard University. Its identification implicated laboratories led by figures associated with the Nobel Prize in Physiology or Medicine and connected fields including work at Max Planck Society and National Institutes of Health.

Structure and Composition

Telomerase is composed of a catalytic protein subunit and an intrinsic RNA component, assembled into a ribonucleoprotein complex studied across labs at Massachusetts Institute of Technology, University of Cambridge, Stanford University, and University of California, San Francisco. The catalytic subunit, often referred to in the literature, is a reverse transcriptase enzyme whose characterization involved groups at European Molecular Biology Laboratory and researchers affiliated with Rockefeller University and Johns Hopkins University. The RNA component contains a template sequence and structural domains conserved across species investigated by teams from University of Oxford and University of Tokyo. Accessory proteins and chaperones that stabilize the holoenzyme have been identified by consortia including investigators at Max Planck Institute for Biology and Institut Pasteur. Structural studies using methods developed at Brookhaven National Laboratory, Argonne National Laboratory, and synchrotron facilities linked to European Synchrotron Radiation Facility have resolved domains that interact with telomeric DNA repeats characterized in organisms studied by Cold Spring Harbor Laboratory investigators.

Mechanism of Action

Telomerase operates by reverse transcription, using its internal RNA as a template to synthesize telomeric DNA repeats, a mechanism elucidated through collaborations between groups at University of California, Berkeley, Yale University, and University of Michigan. The enzyme binds to single-stranded telomeric 3' overhangs, an interaction domain mapped by teams at Princeton University and Carnegie Institution for Science, then catalyzes nucleotide addition in a processive or semi-processive manner studied in vitro by researchers at Sanger Institute and Weizmann Institute of Science. Structural rearrangements during the catalytic cycle were visualized by cryo-electron microscopy efforts coordinated by scientists from Columbia University and University College London. The mechanism involves template translocation, nucleotide selection, and repeat addition processivity, concepts refined by experimentalists working with instrumentation at Los Alamos National Laboratory and computational groups at European Bioinformatics Institute.

Biological Functions and Cellular Roles

Telomerase maintains telomere length homeostasis in stem cells and germline cells, a role demonstrated in comparative studies from University of Chicago and Karolinska Institute. Its activity is central to cellular replicative capacity examined by researchers at Dana-Farber Cancer Institute and Fred Hutchinson Cancer Research Center, and contributes to aging phenotypes studied at Salk Institute and Buck Institute for Research on Aging. In certain somatic tissues and regenerative contexts investigated by teams at University of Pennsylvania and Johns Hopkins Hospital, telomerase supports proliferative potential. Model organism work at Princeton University and University of California, San Diego revealed species-specific regulation and telomere-binding protein interactions, while evolutionary analyses from University of Vienna and University of Montreal traced conservation across eukaryotic lineages.

Regulation and Expression

Expression and activity of telomerase are regulated at transcriptional, post-transcriptional, and post-translational levels, with regulatory networks mapped by labs at Cold Spring Harbor Laboratory, Massachusetts General Hospital, and University of Washington. Promoter control and transcription factor binding dynamics were characterized in studies involving investigators from Imperial College London and University of Toronto. Epigenetic modulation and chromatin context influencing expression were explored by consortia including researchers from EPFL and Georgetown University. Post-translational modifications and ubiquitin-mediated turnover studies were advanced by teams at National Cancer Institute and Ludwig Institute for Cancer Research, while RNA processing and RNP assembly pathways were elucidated in work conducted at Max Delbrück Center and University of Basel.

Clinical Significance and Disease Associations

Dysregulation of telomerase is implicated in cancer biology, as evidenced by studies at Memorial Sloan Kettering Cancer Center, Mayo Clinic, and MD Anderson Cancer Center, where elevated activity supports immortalization in many tumors. Conversely, loss-of-function mutations affecting telomerase components cause telomeropathies, with clinical characterization performed at Cleveland Clinic and St. Jude Children's Research Hospital. Associations with idiopathic pulmonary fibrosis and bone marrow failure syndromes were delineated in collaborative clinical research involving Johns Hopkins Hospital and University College London Hospitals. Epidemiological and translational studies linking telomerase variants to disease risk have engaged consortia including investigators from Broad Institute and Wellcome Trust Sanger Institute.

Research Applications and Therapeutic Potential

Telomerase is a target for anticancer drug development pursued by biotech companies and research centers such as Genentech, Amgen, and GlaxoSmithKline, and has inspired immunotherapy strategies investigated at Memorial Sloan Kettering Cancer Center and Fred Hutchinson Cancer Research Center. Gene therapy and telomerase modulation approaches for regenerative medicine have been explored in preclinical programs at Massachusetts Institute of Technology and Stanford University School of Medicine. Small-molecule inhibitors, antisense oligonucleotides, and vaccine platforms were developed through collaborations involving Novartis and academic partners at University of Zurich and Seoul National University Hospital. Ethical, regulatory, and translational challenges in moving telomerase-based therapies into clinical practice have engaged stakeholders including Food and Drug Administration and regulatory scientists at European Medicines Agency.

Category:Enzymes